ReviewMedical oncology (Northwood, London, England)2025
Huntingtin-interacting protein 1 in cancer progression: a path less explored.
Review in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Huntingtin-interacting protein 1 (HIP1) is a multi-domain heterodimeric protein mainly involved in clathrin-mediated endocytosis and vesicle trafficking. Besides endocytosis, HIP1 regulates proliferation, metastasis, and apoptosis by interacting with different binding partners in different cell types. HIP1 is overexpressed in most cancers and some oncogenic fusion proteins of receptor tyrosine kinases with HIP1 are reported. Clinical significance of HIP1-ALK fusion is being explored in lung cancers, where HIP1 functions as a metastatic suppressor. In some cancers, such as prostate and gliomas, and Merkel cell carcinoma raised HIP1 antibodies in sera can function as prognostic markers. However, there is limited information on the molecular regulators and mechanisms mediated through HIP1 in cancers. In this review, we systematically examine the recent literature on HIP1 to examine its role in various cancer types.
Indexed as
Identifiers
40232352What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.